U.S. markets close in 3 hours 25 minutes
  • S&P 500

    4,418.93
    +16.27 (+0.37%)
     
  • Dow 30

    34,977.34
    +184.67 (+0.53%)
     
  • Nasdaq

    14,877.59
    +97.06 (+0.66%)
     
  • Russell 2000

    2,234.35
    +38.02 (+1.73%)
     
  • Crude Oil

    68.83
    +0.68 (+1.00%)
     
  • Gold

    1,808.10
    -6.40 (-0.35%)
     
  • Silver

    25.31
    -0.16 (-0.61%)
     
  • EUR/USD

    1.1843
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.2150
    +0.0310 (+2.62%)
     
  • GBP/USD

    1.3932
    +0.0048 (+0.34%)
     
  • USD/JPY

    109.7000
    +0.2320 (+0.21%)
     
  • BTC-USD

    38,989.61
    -403.87 (-1.03%)
     
  • CMC Crypto 200

    970.25
    -5.64 (-0.58%)
     
  • FTSE 100

    7,120.43
    -3.43 (-0.05%)
     
  • Nikkei 225

    27,728.12
    +144.04 (+0.52%)
     

Pfizer rethinking U.S. expansion if drug pricing orders implemented

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
A logo for Pfizer is displayed on a monitor on the floor at the NYSE in New York
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) - Pfizer Inc <PFE.N> Chief Executive Albert Bourla said the drugmaker could rethink plans to expand in the United States if the country implements an executive order signed by President Donald Trump last week that would tie the prices Medicare patients pay for drugs to those paid by other countries.

Trump on Friday signed four executive orders aimed at lowering the prices Americans pay for prescription drugs, as he faces an uphill re-election battle and criticism over his handling of the coronavirus pandemic.

"These new executive orders could force us to rethink those plans, consider job reductions and add to the economic and health anxiety already widely felt in our country," Bourla said on the company's earnings conference call.

(Reporting by Michael Erman; Editing by Chris Reese)